Tenapanor: A Comprehensive Monograph on a First-in-Class NHE3 Inhibitor for Gastroenterological and Nephrological Disorders

Executive Summary

Tenapanor is a first-in-class, orally administered, small-molecule inhibitor of the intestinal sodium/hydrogen exchanger isoform 3 (NHE3).[1] Characterized by its minimal systemic absorption, Tenapanor exerts its pharmacological effects locally within the gastrointestinal tract, a property that underpins both its therapeutic efficacy and its distinct safety profile.[4] This targeted action has led to its approval for two separate and mechanistically distinct indications.

For gastroenterological applications, Tenapanor is marketed as Ibsrela® for the treatment of adults with Irritable Bowel Syndrome with Constipation (IBS-C).[1] By inhibiting NHE3, it reduces sodium absorption from the gut, leading to an osmotic influx of water into the lumen. This "retainagogue" effect softens stool, increases bowel movement frequency, and alleviates constipation. Concurrently, preclinical and clinical evidence suggests Tenapanor reduces visceral hypersensitivity, thereby addressing the abdominal pain and bloating characteristic of IBS-C.[4] Its efficacy was established in the comprehensive T3MPO Phase 3 clinical trial program, which demonstrated statistically significant and sustained improvements in the composite endpoint of abdominal pain and bowel movement frequency compared to placebo.[8]

For nephrological applications, Tenapanor is marketed as Xphozah® to reduce serum phosphorus in adults with Chronic Kidney Disease (CKD) on dialysis.[1] Its unique mechanism as a non-binder phosphate absorption inhibitor differentiates it from traditional phosphate binders.[5] NHE3 inhibition by Tenapanor is understood to tighten intestinal paracellular junctions, thereby reducing the primary pathway for passive phosphate absorption.[5] The pivotal PHREEDOM and AMPLIFY trials demonstrated its efficacy both as a monotherapy and as an effective add-on therapy for patients inadequately controlled on phosphate binders, respectively.[13] This dual-mechanism approach offers a new paradigm for managing refractory hyperphosphatemia and can significantly reduce the high pill burden associated with binder regimens.[15]

The primary adverse event associated with Tenapanor is diarrhea, an on-target effect of its mechanism of action.[16] A significant safety concern, highlighted by a boxed warning for Ibsrela, is the risk of serious dehydration in pediatric patients, leading to a contraindication in children under 6 years of age.[16] Overall, Tenapanor represents a significant therapeutic innovation, providing a novel, targeted treatment for specific patient populations in both gastroenterology and nephrology.

Section 1: Foundational Profile of Tenapanor

1.1 Chemical Identity and Nomenclature

Tenapanor is a synthetic, non-systemic small molecule that represents the first approved therapeutic agent in its class.[1] It is utilized clinically in the form of tenapanor hydrochloride.[2]

Chemically, the molecule is classified as a 4-phenyltetrahydroisoquinoline, a structural class defined by the presence of a phenyl group attached to the fourth carbon atom of a tetrahydroisoquinoline core.[1] The full molecular structure also incorporates sulfonamide moieties, placing it within this broad chemical family known for a wide range of therapeutic activities.[21]

The systematic International Union of Pure and Applied Chemistry (IUPAC) name for Tenapanor is N,N'-(10,17,-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosane-1,26-diyl)bis(benzenesulfonamide).[2] This complex nomenclature describes a large, symmetrical molecule featuring two identical (4S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline units at its termini. These units are connected by a long, flexible polyether-polyurea linker. This unique architecture—with its large size, high polarity, and flexible linker—is a deliberate design feature that contributes significantly to the drug's key pharmacokinetic property of poor membrane permeability, thereby confining its action to the gastrointestinal lumen.

During its development by Ardelyx, Inc., Tenapanor was identified by several developmental codes, including AZD1722 and RDX5791.[23]

Table 1: Key Identifiers and Chemical Properties of Tenapanor

Property	Value	Source(s)
Generic Name	Tenapanor	1
Drug Type	Small Molecule	1
Chemical Class	4-Phenyltetrahydroisoquinoline; Sulfonamide	1
CAS Number	1234423-95-0 (free base)	1
	1234365-97-9 (dihydrochloride salt)	20
DrugBank ID	DB11761	1
PubChem CID	71587953	2
UNII Codes	WYD79216A6 (free base)	2
	50605O2ZNS (hydrochloride)	2
ATC Code	A06AX08	2
Molecular Formula	C50​H66​Cl4​N8​O10​S2​	27
Molecular Weight	1145.05 g/mol	23

1.2 Physicochemical Properties and Formulation

Tenapanor was first designed and synthesized in 2012.[1] A key physicochemical property is its practical insolubility in aqueous media, which is a primary determinant of its minimal systemic absorption following oral administration.[28] This property ensures that the drug remains concentrated within the gastrointestinal tract to exert its local pharmacological effects.

Tenapanor is formulated as oral, film-coated tablets for administration.[2] The available dosage strengths are tailored to its distinct indications. For the treatment of IBS-C, it is available as 50 mg tablets under the brand name Ibsrela.[29] For the reduction of serum phosphorus in CKD, it is available as 10 mg, 20 mg, and 30 mg tablets under the brand name Xphozah.[29] The availability of multiple lower strengths for the Xphozah formulation facilitates dose adjustments to manage gastrointestinal tolerability in the CKD patient population.[29]

Section 2: Preclinical and Clinical Pharmacology

The pharmacological profile of Tenapanor is defined by its targeted, localized action within the gastrointestinal tract. Its novel mechanism of action and its pharmacokinetic properties of minimal systemic exposure are intrinsically linked, creating a therapeutic agent that maximizes local efficacy while minimizing the potential for systemic adverse events.

2.1 Mechanism of Action (MoA): Inhibition of NHE3 and Downstream Physiological Effects

Tenapanor is a potent and selective inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3), a protein encoded by the SLC9A3 gene.[1] NHE3 is an antiporter located on the apical membrane of enterocytes lining the small intestine and colon.[1] Its physiological role is to facilitate the absorption of dietary sodium from the intestinal lumen into the body in exchange for intracellular protons.[1] This process is a dominant pathway for transepithelial sodium absorption.[3] Tenapanor's therapeutic effects in both IBS-C and hyperphosphatemia stem directly from the inhibition of this single target, which produces a cascade of distinct downstream physiological changes.

2.1.1 Effect on Sodium and Water Transport: The "Retainagogue" Effect

In the context of IBS-C, Tenapanor's primary therapeutic action is driven by its modulation of intestinal fluid balance. By blocking NHE3, Tenapanor prevents luminal sodium absorption, causing sodium ions to be retained within the gut.[1] This accumulation of solutes increases the osmotic pressure within the intestinal lumen, which in turn draws water from the body into the gut to maintain osmotic equilibrium.[1]

The resulting increase in intestinal water content has two key benefits for patients with constipation: it softens stool consistency and it increases stool volume, which promotes motility.[1] This mechanism of action is distinct from that of secretagogue drugs (e.g., guanylate cyclase-C agonists), which actively stimulate the secretion of chloride and bicarbonate ions into the lumen to draw water in. Tenapanor, by contrast, works by preventing the reabsorption of sodium and water that is already present, acting as a "retainagogue".[4]

2.1.2 Effect on Phosphate Absorption: The "Phosphate Absorption Inhibitor" Effect

For the treatment of hyperphosphatemia in CKD patients, Tenapanor employs a novel, non-binder mechanism to reduce phosphate absorption.[5] Unlike traditional phosphate binders that physically sequester dietary phosphate to form unabsorbable complexes, Tenapanor modulates the intestinal barrier itself.[5]

The primary route for intestinal phosphate absorption, particularly under high-phosphate conditions, is the paracellular pathway—the space between adjacent enterocytes.[5] The permeability of this pathway is regulated by tight junction proteins. Tenapanor's inhibition of NHE3 leads to an accumulation of intracellular protons, which is believed to trigger a conformational change in these tight junction proteins.[4] This change effectively "tightens" the paracellular pathway, reducing its permeability and thereby blocking the passive absorption of phosphate from the gut into the bloodstream.[5]

Furthermore, Tenapanor has been shown to prevent a potential compensatory mechanism. It can decrease the expression of the sodium-phosphorus 2b transport protein (NaPi2b), which is responsible for active, transcellular phosphate absorption, thus providing a more comprehensive blockade of intestinal phosphate uptake.[37] This dual-mechanism approach—inhibiting paracellular phosphate flux and downregulating a key transcellular transporter—underpins its efficacy in lowering serum phosphorus.

2.1.3 Effect on Visceral Hypersensitivity: Pain Reduction

A critical component of Tenapanor's efficacy in IBS-C is its ability to reduce abdominal pain and visceral hypersensitivity, an effect that appears to be at least partially independent of its laxative action.[4] Several preclinical mechanisms have been elucidated.

First, Tenapanor has been shown to strengthen the intestinal barrier function. In experimental models, it increases transepithelial electrical resistance (TEER), a measure of the integrity of the tight junctions between cells. This reduction in intestinal permeability may prevent luminal antigens and inflammatory mediators from crossing the gut barrier and activating underlying sensory nerves.[4]

Second, Tenapanor appears to have a direct effect on the excitability of sensory neurons. In animal models of visceral hypersensitivity, Tenapanor reversed the hyperexcitability of colon-specific dorsal root ganglia (DRG) neurons.[4] This effect may be mediated through the modulation of the transient receptor potential vanilloid type 1 (TRPV1) channel, a key nociceptive signaling pathway involved in pain perception.[4] This triad of therapeutic actions—alleviating constipation, reducing pain, and mitigating bloating—addresses the complete symptom cluster of IBS-C, which may explain the high patient-reported satisfaction observed in real-world data.[43]

2.2 Pharmacodynamics (PD)

The pharmacodynamic effects of Tenapanor are consistent with its mechanism of action and are confined to the gastrointestinal tract and its physiological consequences. Oral administration in both animal models and human subjects results in dose-dependent increases in fecal sodium and water content, coupled with a corresponding decrease in urinary sodium excretion.[4] Similarly, it leads to increased fecal phosphate excretion and decreased urinary phosphate excretion.[4]

The potency of Tenapanor against its target is high, with in vitro studies demonstrating half-maximal inhibitory concentration (IC50​) values of 5 nM against human NHE3 and 10 nM against rat NHE3.[25] The drug exhibits excellent selectivity; concentrations up to 10–30 µM do not inhibit other key intestinal transporters, including NHE1, NHE2, TGR5, ASBT, or NaPiIIb, ensuring its action is highly targeted.[25] The pharmacodynamic effects are also reversible, with physiological markers such as urine sodium returning to baseline levels within two days of drug discontinuation, confirming that its effects are dependent on its continued presence in the gut lumen.[4]

2.3 Pharmacokinetics (PK): A Profile of Localized Action

The pharmacokinetic profile of Tenapanor is central to its clinical utility and safety, characterized by its design as a "gut-restricted" agent that acts locally with minimal entry into the systemic circulation.

• Absorption: Following oral administration, Tenapanor undergoes very minimal systemic absorption.[1] In the majority of plasma samples collected during clinical studies, drug concentrations were below the lower limit of quantitation (<0.5 ng/mL).[1] This fundamental property precludes the calculation of standard pharmacokinetic parameters like area under the curve (AUC) or maximum concentration ( Cmax​) for the parent drug and is the primary reason for its favorable systemic safety profile.
• Distribution: Due to its negligible absorption, systemic distribution is not a significant factor. In the rare instances where it can be measured, both Tenapanor and its primary metabolite, M1, are highly bound to plasma proteins (approximately 99% and 97%, respectively), although the specific binding proteins have not been identified.[1]
• Metabolism: Tenapanor is metabolized to its principal, inactive metabolite, M1, primarily via cytochrome P450 3A4 and 3A5 (CYP3A4/5) enzymes.[1] Given the low systemic drug exposure, this metabolic conversion is presumed to occur predominantly within the enterocytes of the intestine rather than in the liver.[1] Unlike the parent drug, the M1 metabolite is detectable in plasma, reaching a Cmax​ of approximately 15 ng/mL at steady state, but it is not active against NHE3.[1]
• Excretion: The primary route of elimination for Tenapanor and its metabolites is fecal. After administration of a radiolabeled dose, approximately 79% of the radioactivity was recovered in the feces within 240 hours. A substantial portion of the dose, around 65%, is excreted as unchanged parent drug, underscoring its poor absorption.[1] A minor fraction (~9%) of the administered dose is excreted in the urine, almost entirely as metabolites.[1]

Section 3: Clinical Development and Efficacy in Irritable Bowel Syndrome with Constipation (IBS-C)

The clinical utility of Tenapanor for the treatment of IBS-C was rigorously established through the T3MPO Phase 3 program. This program was designed to meet the stringent regulatory requirements for IBS-C therapies, focusing on a composite endpoint that captures improvement in both the constipation and abdominal pain components of the disorder.

3.1 The T3MPO Phase 3 Clinical Trial Program: An Overview

The pivotal evidence for Tenapanor's approval for IBS-C comes from two large-scale, randomized, double-blind, placebo-controlled Phase 3 trials: T3MPO-1 (NCT02621892) and T3MPO-2 (NCT02686138).[2] These were supported by a long-term safety extension study, T3MPO-3 (NCT02621892).[34]

The trials enrolled adult patients aged 18 to 75 who met the Rome III diagnostic criteria for IBS-C.[3] The pooled patient population across the trials was predominantly female (~82%) with a mean age of approximately 45 years, reflecting the typical demographic of this condition.[3] The standard dosage regimen evaluated in these trials was Tenapanor 50 mg administered orally twice daily (BID).[3]

The primary efficacy endpoint for both trials was the proportion of "6/12-week combined responders." This is a rigorous, composite endpoint defined by the U.S. Food and Drug Administration (FDA), requiring a patient to experience, within the same week, both a reduction of at least 30% in their average weekly worst abdominal pain score and an increase of at least one complete spontaneous bowel movement (CSBM) from baseline. To be classified as a responder, a patient had to meet these dual criteria for at least 6 of the first 12 weeks of the treatment period.[3]

3.2 Analysis of the T3MPO-1 Trial: Efficacy and Onset of Action

The T3MPO-1 trial was designed with a 12-week double-blind treatment period, followed by a 4-week randomized withdrawal period to assess the persistence of effect.[8] The intention-to-treat (ITT) analysis included 606 patients, with 307 randomized to Tenapanor and 299 to placebo.[8]

The trial successfully met its primary endpoint. The 6/12-week combined responder rate was significantly higher in the Tenapanor group compared to the placebo group: 27.0% vs. 18.7% (p=0.020).[8]

Analysis of secondary endpoints further supported the drug's efficacy. Significant improvements were observed in the individual components of the primary endpoint, including the abdominal pain responder rate (44.0% vs. 33.1%, p=0.008).[50] Tenapanor also demonstrated superiority over placebo for more stringent durable responder endpoints, such as the 9-of-12-week combined responder rate (13.7% vs. 3.3%, p<0.001), indicating a sustained and meaningful response for a subset of patients.[50]

3.3 Analysis of the T3MPO-2 Trial: Long-Term Efficacy and Symptom Improvement

The T3MPO-2 trial was designed to evaluate the long-term efficacy and safety of Tenapanor over a 26-week treatment period.[3] The ITT population consisted of 593 patients (293 in the Tenapanor arm, 300 in the placebo arm).[3]

The results of T3MPO-2 were highly consistent with, and numerically stronger than, those of T3MPO-1. The trial met its primary endpoint with a 6/12-week combined responder rate of 36.5% for Tenapanor versus 23.7% for placebo (p<0.001).[3]

Crucially, the trial demonstrated that the therapeutic benefits of Tenapanor were sustained over the long term. Statistically significant improvements in both abdominal and bowel symptoms were observed as early as the first week of treatment and were maintained throughout the entire 26-week study period.[9] This durability was further confirmed by key secondary endpoints, such as the 13-of-26-week combined responder rate.[9] A post-hoc analysis of the T3MPO data revealed that Tenapanor improved abdominal symptoms regardless of changes in bowel movement frequency, providing clinical support for a separate, direct mechanism of pain relief beyond its laxative effect.[7] This finding is significant, as it suggests Tenapanor is not merely treating constipation with a secondary benefit on pain, but rather is addressing both core symptoms of IBS-C concurrently.

Table 2: Summary of Key Efficacy Outcomes from the T3MPO-1 and T3MPO-2 Trials

Efficacy Endpoint	T3MPO-1 (12 Weeks)	T3MPO-2 (26 Weeks)
Patient N (Tenapanor/Placebo)	307 / 299	293 / 300
Primary Endpoint: 6/12-Week Combined Responder Rate (%)	27.0% vs. 18.7% (p=0.020)	36.5% vs. 23.7% (p<0.001)
Key Secondary: 6/12-Week Abdominal Pain Responder Rate (%)	44.0% vs. 33.1% (p=0.008)	49.5% vs. 36.3% (p<0.001)
Key Secondary: 6/12-Week CSBM Responder Rate (%)	33.9% vs. 29.4% (p=0.27)	47.1% vs. 29.7% (p<0.001)
Key Secondary: Durable 9/12-Week Combined Responder Rate (%)	13.7% vs. 3.3% (p<0.001)	23.5% vs. 11.0% (p<0.001)
Source(s):		3

Section 4: Clinical Development and Efficacy in Hyperphosphatemia

Tenapanor's development for hyperphosphatemia represents a paradigm shift in the management of this common and serious complication of CKD. Moving beyond the traditional approach of binding dietary phosphate, Tenapanor introduces a new strategy of actively blocking its absorption at the intestinal level. This novel mechanism has been evaluated in a comprehensive clinical program establishing its efficacy both as a standalone therapy and as a synergistic partner to existing treatments.

4.1 A Novel, Non-Binder Approach to Phosphate Management

The management of hyperphosphatemia has historically relied exclusively on phosphate binders, which carry a significant pill burden and are often insufficient to achieve target serum phosphorus levels for many patients on dialysis.[15] Tenapanor's mechanism as a phosphate absorption inhibitor that primarily blocks the paracellular pathway offers a fundamentally new therapeutic option.[5] This allows it to be used as a monotherapy for patients who are intolerant to binders or, perhaps more importantly, as an add-on therapy to create a dual-mechanism blockade of phosphate absorption for patients with refractory hyperphosphatemia.[11]

4.2 The PHREEDOM Trial: Tenapanor as Monotherapy

The PHREEDOM trial (NCT03427125) was a large, 52-week, Phase 3 study designed to evaluate the efficacy and safety of Tenapanor 30 mg BID as a monotherapy.[13] The study included an active-control period with sevelamer carbonate and a randomized withdrawal period against placebo.[13]

During the initial 26-week open-label treatment period, Tenapanor monotherapy demonstrated a clinically meaningful and statistically significant reduction in serum phosphorus. In the pre-specified efficacy analysis set, the mean serum phosphorus level decreased from a baseline of 7.7 mg/dL to 5.1 mg/dL.[13]

The trial's primary endpoint was assessed during the subsequent 12-week randomized withdrawal period, where patients who had responded to Tenapanor were re-randomized to either continue Tenapanor or switch to placebo. The results were definitive: patients continuing on Tenapanor maintained control of their serum phosphorus, while those switched to placebo experienced a rapid rebound. The difference in the change in serum phosphorus between the Tenapanor and placebo groups was -1.4 mg/dL (p<0.0001), confirming that the phosphate-lowering effect was attributable to Tenapanor.[13]

4.3 The AMPLIFY Trial: Tenapanor as Add-On Therapy

The AMPLIFY trial (NCT03824587) was a 4-week, randomized, placebo-controlled Phase 3 study specifically designed to evaluate Tenapanor as an add-on therapy in patients whose hyperphosphatemia was inadequately controlled despite stable treatment with phosphate binders.[14] This trial directly tested the clinical utility of the dual-mechanism approach.

The study met its primary endpoint with high statistical significance. The addition of Tenapanor to an existing binder regimen resulted in a mean reduction in serum phosphorus from baseline of -0.84 mg/dL, compared to a reduction of only -0.19 mg/dL in the group that received placebo plus binders (p<0.001).[14]

Key secondary endpoints underscored the clinical relevance of this finding. A significantly greater proportion of patients in the Tenapanor combination arm achieved the clinically important serum phosphorus target of <5.5 mg/dL compared to the binder-only arm (up to 49.1% vs. 23.5%, respectively).[58] Furthermore, Tenapanor treatment led to a significant reduction in levels of fibroblast growth factor 23 (FGF23), a hormone implicated in the adverse cardiovascular outcomes associated with disordered mineral metabolism in CKD.[58] These results provide strong evidence that Tenapanor can synergistically enhance the efficacy of phosphate binders, allowing more patients to reach their therapeutic goals.

4.4 Long-Term Phosphate Control: Insights from the NORMALIZE Study

The NORMALIZE study (NCT03988920) was a long-term, Phase 4 trial that enrolled patients who had completed the PHREEDOM study, following them for up to an additional 18 months.[60] The study's ambitious objective was to assess whether long-term treatment with Tenapanor, either alone or in combination with sevelamer, could help patients achieve and maintain normal serum phosphate levels (defined as ≥2.5 and ≤4.5 mg/dL).[61]

The study demonstrated the durability of Tenapanor's effect and its potential to achieve more stringent phosphate control than is typically seen with standard care. The primary endpoint was met, with 33.3% of patients in the efficacy analysis set achieving a serum phosphorus level within the normal range.[61] This finding suggests that a long-term strategy incorporating Tenapanor can lead to a substantial improvement in phosphate management for the dialysis population. The ability to reduce the significant pill burden associated with binder monotherapy is a critical secondary benefit. One study in Japanese hemodialysis patients found that adding Tenapanor allowed over 70% of patients to reduce their binder tablet count by at least 30%, with 28% being able to discontinue binders altogether, highlighting a major patient-centered advantage.[15]

Table 3: Summary of Key Efficacy Outcomes from the PHREEDOM and AMPLIFY Trials

Trial	Therapy	Primary Endpoint Definition	Primary Endpoint Result	Key Secondary Endpoint
PHREEDOM	Monotherapy	Difference in change in serum phosphorus between Tenapanor and placebo during a 12-week randomized withdrawal period.	−1.4 mg/dL (p<0.0001)	N/A
AMPLIFY	Add-on to Binders	Change in serum phosphorus from baseline to Week 4 for Tenapanor + Binder vs. Placebo + Binder.	−0.84 mg/dL vs. −0.19 mg/dL (p<0.001)	Up to 49.1% of patients on Tenapanor achieved sP <5.5 mg/dL vs. 23.5% on placebo.
Source(s):		13

Section 5: Comprehensive Safety and Tolerability Assessment

The safety profile of Tenapanor is largely defined by its localized action within the gastrointestinal tract. Its minimal systemic absorption results in a favorable systemic safety profile, with the most prominent adverse events being direct, on-target pharmacological effects within the gut.

5.1 Adverse Event Profile from Clinical Trials

The adverse event profile of Tenapanor differs in incidence, but not in type, between its two approved indications.

• IBS-C Trials (Ibsrela): In the pooled data from the T3MPO trials, the most common adverse reactions reported at an incidence of ≥2% and greater than placebo were diarrhea (16%), abdominal distension (3%), flatulence (3%), and dizziness (2%).[16]
• Hyperphosphatemia Trials (Xphozah): In the CKD patient population, the incidence of diarrhea was substantially higher. Across the clinical trials, diarrhea was the only adverse reaction reported in at least 5% of patients, with an incidence ranging from 43% to 53%.[17] This marked difference in incidence likely reflects a combination of factors, including underlying gut dysmotility in uremic patients and potential differences in gut fluid handling.
• Other Adverse Events: Less common adverse reactions reported in IBS-C trials included rectal bleeding and abnormal gastrointestinal sounds (<2% incidence).[18] Importantly, due to its negligible systemic exposure, Tenapanor has not been associated with elevations in serum liver enzymes or instances of clinically apparent liver injury, earning it a LiverTox likelihood score of "E" (unlikely cause of liver injury).[19]

5.2 In-Depth Analysis of Diarrhea as the Primary Adverse Event

Diarrhea is not an off-target side effect of Tenapanor but rather an extension of its intended mechanism of action—the retention of sodium and water in the intestinal lumen.[16] This creates a unique clinical context where the primary adverse event is mechanistically linked to the therapeutic effect.

• Characteristics: In clinical trials for both indications, episodes of diarrhea were typically characterized as mild-to-moderate in severity and were often transient, resolving with continued treatment or dose reduction.[9] The onset is usually soon after initiating therapy but can occur at any point during treatment.[17]
• Severity and Discontinuation: While most cases are manageable, severe diarrhea can occur. It was reported in 2.5% of Ibsrela-treated patients and 5% of Xphozah-treated patients.[16] Diarrhea is the most common reason for discontinuing the drug, with discontinuation rates of 6.5% in the IBS-C trials.[8]
• Management: The clinical management strategy for diarrhea is clear. If severe diarrhea develops, treatment should be suspended and the patient rehydrated.[16] For the Xphozah indication, the prescribing information allows for dose adjustment (e.g., from 30 mg BID to 20 mg or 10 mg BID) to manage gastrointestinal tolerability while aiming to maintain the phosphate-lowering effect.[29]

5.3 Regulatory Warnings, Contraindications, and Precautions

The prescribing information for Tenapanor includes critical warnings and contraindications, primarily related to pediatric safety.

• Boxed Warning (Ibsrela): RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS This prominent warning is based on nonclinical studies in young juvenile rats where administration of Tenapanor led to deaths that were presumed to be caused by severe dehydration.16 Based on these findings:
• Tenapanor is contraindicated in patients less than 6 years of age.[16]
• Use of Tenapanor should be avoided in patients 6 years to less than 12 years of age.[16]
• The safety and effectiveness of Tenapanor have not been established in any pediatric population (<18 years of age).[16]
• Other Contraindications: Tenapanor is also contraindicated in patients with a known or suspected mechanical gastrointestinal obstruction.[16]
• Pregnancy and Lactation: Due to its minimal systemic absorption, maternal use of Tenapanor is not expected to result in fetal exposure to the drug.[30] Furthermore, studies in lactating women have shown that neither Tenapanor nor its major metabolite were detected in breastmilk, suggesting that no special precautions are necessary during breastfeeding.[10]

5.4 Drug-Drug Interaction (DDI) Potential

The potential for systemic drug-drug interactions with Tenapanor is low due to its minimal absorption. However, clinically relevant interactions can occur within the gastrointestinal tract.

• Inhibition of OATP2B1: Tenapanor is an inhibitor of the intestinal uptake transporter Organic Anion-Transporting Polypeptide 2B1 (OATP2B1).[29] This can decrease the absorption and systemic exposure of drugs that are substrates of this transporter.
• A significant clinical interaction has been demonstrated with enalapril. Co-administration with Tenapanor reduced the peak exposure (Cmax​) of enalapril and its active metabolite, enalaprilat, by approximately 70%, and total exposure (AUC) by 50-65%.[29] This necessitates close monitoring of blood pressure and may require an increased dose of enalapril when used concomitantly.[29]
• Other OATP2B1 substrates, such as certain statins (e.g., atorvastatin, rosuvastatin), bosentan, and glyburide, may also have reduced exposure. Caution and clinical monitoring are advised when co-administered with Tenapanor.[29]
• Binding Interactions: Tenapanor can be bound by sodium polystyrene sulfonate (SPS), a potassium binder used to treat hyperkalemia. To avoid this interaction, administration of the two drugs should be separated by at least 3 hours.[29]

Table 4: Incidence of Common Adverse Reactions in IBS-C and Hyperphosphatemia Trials

Adverse Reaction	Ibsrela for IBS-C (Pooled Data)	Xphozah for Hyperphosphatemia (Pooled Data)
	% Tenapanor	% Placebo
Diarrhea (any)	16%	4%
Diarrhea (severe)	2.5%	0.2%
Abdominal Distension	3%	<1%
Flatulence	3%	1%
Dizziness	2%	<1%
Source(s):		16

Section 6: Regulatory Status and Prescribing Information

The regulatory journey of Tenapanor highlights its development for two distinct therapeutic areas, culminating in approvals from several major global health authorities and a strategic dual-branding approach by its developer, Ardelyx, Inc..[2]

6.1 Global Regulatory Approvals and Development Timeline

• United States (FDA): Tenapanor has received two separate approvals from the U.S. FDA.
• Ibsrela (for IBS-C): First approved on September 12, 2019, for the treatment of IBS-C in adults.[1]
• Xphozah (for Hyperphosphatemia): Approved on October 17, 2023, to reduce serum phosphorus in adults with CKD on dialysis as an add-on therapy.[1] The path to this second approval was complex, involving the issuance of a Complete Response Letter in July 2021 before the application was ultimately successful, indicating significant regulatory review.[54]
• International Approvals:
• Japan (PMDA): Tenapanor is approved for hyperphosphatemia and is marketed by Kyowa Kirin under the brand name PHOZEVEL®.[11]
• Canada (Health Canada): Tenapanor is approved for the treatment of IBS-C under the brand name Ibsrela.[2]
• China: A New Drug Application for the hyperphosphatemia indication has been submitted by the licensee Fosun Pharma.[11]
• European Union (EMA): As of the latest available information, Tenapanor does not have a marketing authorization granted through the EMA's centralized procedure.[42] A June 2024 EMA document noted that a "Product Specific Waiver" for a Paediatric Investigation Plan had been granted, which is a procedural step in the regulatory process but does not constitute an approval.[74] Therefore, Tenapanor is not currently authorized for use across the European Union.

6.2 Approved Indications, Brand Formulations, and Dosing

The marketing of Tenapanor under two different brand names with distinct formulations is a deliberate strategy to target separate medical specialties—gastroenterology and nephrology—and to prevent prescribing errors between the different indications and dosing regimens.

• Ibsrela® (for IBS-C)
• Indication: Indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.[1]
• Dosage Form: 50 mg film-coated tablets.[29]
• Recommended Dosing: The recommended dosage is 50 mg taken orally twice daily.[18]
• Xphozah® (for Hyperphosphatemia)
• Indication: Indicated to reduce serum phosphorus in adults with CKD on dialysis as an add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.[1]
• Dosage Form: 10 mg, 20 mg, and 30 mg film-coated tablets.[29]
• Recommended Dosing: The recommended starting dosage is 30 mg taken orally twice daily. The dosage can be adjusted as needed to manage gastrointestinal tolerability.[29]
• Administration Instructions (Applicable to Both Brands):
• Tablets should be taken immediately prior to the morning meal (or breakfast) and immediately prior to the evening meal (dinner).[1]
• If a dose is missed, the patient should skip the missed dose and take the next dose at the regularly scheduled time. Doses should not be doubled to make up for a missed dose.[68]

Section 7: Comparative Therapeutic Landscape

Tenapanor's entry into the therapeutic armamentarium for both IBS-C and hyperphosphatemia is defined by its unique mechanism of action, which positions it as a distinct option relative to established therapies. Its role is best understood by comparing its profile to that of other available agents in each therapeutic area.

7.1 Tenapanor in the Context of IBS-C Management

Tenapanor provides a novel mechanistic approach for patients with IBS-C, particularly for those who have had an inadequate response to or cannot tolerate other treatments.

• vs. Guanylate Cyclase-C (GC-C) Agonists (Linaclotide, Plecanatide): Linaclotide (Linzess) and plecanatide (Trulance) are secretagogues that increase intestinal fluid by activating the GC-C receptor.76 In contrast, Tenapanor is a retainagogue that works by inhibiting NHE3.35 While both classes effectively treat constipation and abdominal pain, a network meta-analysis suggested that linaclotide may rank higher for the composite endpoint, whereas Tenapanor ranked first for the specific symptom of bloating.77 Real-world user satisfaction ratings appear to favor Tenapanor (Ibsrela average rating 8.9/10) over linaclotide (Linzess average rating 6.7/10), which may reflect differences in tolerability or efficacy on the full symptom cluster for some patients.43 The primary side effect for both classes is diarrhea.76
• vs. Chloride Channel Activators (Lubiprostone): Lubiprostone (Amitiza) activates type-2 chloride channels to increase intestinal fluid secretion.78 Its indication for IBS-C is limited to adult women, whereas Tenapanor is approved for all adults.78 While both can cause diarrhea, lubiprostone is also associated with a significant incidence of nausea, which is less common with Tenapanor.78 As with linaclotide, patient-reported satisfaction ratings are substantially higher for Tenapanor (8.8/10) compared to lubiprostone (5.6/10).79

Table 5: Comparative Profile of Prescription Therapies for IBS-C

Feature	Tenapanor (Ibsrela)	Linaclotide (Linzess)	Lubiprostone (Amitiza)
Mechanism of Action	NHE3 Inhibitor (Retainagogue)	GC-C Agonist (Secretagogue)	Chloride Channel Activator
Dosing Frequency	Twice daily	Once daily	Twice daily
Administration	Immediately before meals	On an empty stomach	With food and water
Key Efficacy	Improves constipation, pain, and bloating	Improves constipation and pain	Improves constipation and pain
Primary Side Effects	Diarrhea, abdominal distension, flatulence	Diarrhea, abdominal pain, gas	Nausea, diarrhea
Pediatric Use	Contraindicated <6 yrs; Avoid use 6-<12 yrs	Contraindicated <2 yrs; Avoid use 2-<18 yrs	Not approved for children
Source(s):		16

7.2 Tenapanor in the Context of Hyperphosphatemia Management

In nephrology, Tenapanor's role is not to replace phosphate binders but to offer a new strategy for achieving phosphate control, especially in difficult-to-treat patients.

• vs. Phosphate Binders (Sevelamer, Lanthanum Carbonate, etc.): The fundamental difference lies in the mechanism: Tenapanor is a phosphate absorption inhibitor, whereas sevelamer, lanthanum carbonate, and others are phosphate binders.5 This distinction is critical, as it means their mechanisms are complementary, not redundant. Preclinical and clinical data have confirmed that the combination of Tenapanor and a binder (like sevelamer) is synergistic, leading to a more profound reduction in phosphate absorption than either agent alone.14 The most significant clinical advantage of Tenapanor in this setting is the reduction in pill burden. Patients on phosphate binders often require multiple large tablets with every meal, leading to adherence challenges.[15] Tenapanor's simple one-tablet, twice-daily regimen can either replace binders in intolerant patients or, more commonly, allow for a significant reduction in the number of binder pills required, improving quality of life and potentially adherence.[15] This benefit, however, is offset by Tenapanor's significantly higher cost compared to generic binders, which can be a major barrier to access.[52] In terms of side effects, Tenapanor's primary issue is diarrhea, while binders can cause a range of GI issues, and some carry specific concerns (e.g., risk of hypercalcemia with calcium-based binders, lanthanum deposition with lanthanum carbonate).[52]

Table 6: Comparative Profile of Therapies for Hyperphosphatemia

Feature	Tenapanor (Xphozah)	Sevelamer	Lanthanum Carbonate
Mechanism of Action	Phosphate Absorption Inhibitor (NHE3)	Non-calcium Phosphate Binder	Non-calcium Phosphate Binder
Role in Therapy	Monotherapy or Add-on	Monotherapy or in Combination	Monotherapy or in Combination
Daily Pill Burden	2 tablets	High (often 6+ tablets)	Moderate (often 3+ tablets)
Cost	High	Low (generic available)	Moderate
Key Side Effect Profile	Diarrhea (43-53%)	GI upset, constipation	GI upset, nausea
Effect on Serum Minerals	No effect on serum calcium	No effect on serum calcium	No effect on serum calcium
Source(s):		5

Section 8: Synthesis and Future Perspectives

8.1 Summary of Tenapanor's Clinical Utility and Unique Therapeutic Position

Tenapanor has successfully established itself as a valuable therapeutic agent by addressing clear unmet needs in two distinct medical fields. Its clinical utility is a direct result of a sophisticated drug design that created a potent, gut-restricted inhibitor of NHE3, maximizing local efficacy while minimizing systemic risk.

In gastroenterology, Tenapanor (Ibsrela) offers a comprehensive treatment for the symptom cluster of IBS-C. Its unique "retainagogue" mechanism, combined with its ability to directly modulate visceral hypersensitivity, provides a multi-faceted approach to relieving not only constipation but also the burdensome symptoms of abdominal pain and bloating. For patients who have failed or cannot tolerate existing secretagogue therapies, Tenapanor provides a novel and effective alternative.

In nephrology, Tenapanor (Xphozah) represents a paradigm shift from the long-standing reliance on phosphate binders. By introducing the concept of a phosphate absorption inhibitor, it provides a new tool for managing the pervasive and challenging problem of hyperphosphatemia in dialysis patients. Its role as an add-on therapy, enabling a dual-mechanism approach, is particularly valuable for the large proportion of patients who cannot achieve target phosphate levels with binders alone. Furthermore, its ability to significantly reduce the high pill burden associated with binder regimens is a major patient-centered benefit that can improve adherence and quality of life.

Across both indications, the primary clinical consideration is balancing its novel efficacy against its main on-target side effect, diarrhea. The successful integration of Tenapanor into clinical practice hinges on appropriate patient selection and proactive management of this predictable adverse event through patient education and, where applicable, dose titration.

8.2 Ongoing Research and Potential Future Applications

The clinical development of Tenapanor is ongoing, with research aimed at expanding its utility to new patient populations and potentially new indications.

• Pediatric Use in IBS-C: Recognizing the need for effective treatments for younger patients, a Phase 3 clinical trial (NCT05643534) is currently recruiting to evaluate the safety and efficacy of Tenapanor in adolescents (aged 12 to less than 18 years) with IBS-C.[83] Positive results from this study could lead to a label expansion, offering a new option for this underserved population. However, due to the established safety risks, its use in younger children is unlikely.
• Cystic Fibrosis-Related Constipation: The mechanism of Tenapanor may also be beneficial for other forms of constipation. A Phase 3 trial (NCT06810167) is actively recruiting to assess Tenapanor as a treatment for constipation related to cystic fibrosis, a condition where altered intestinal fluid and electrolyte transport is a key pathophysiological feature.[84]
• Future Outlook: The initial development of Tenapanor also explored its potential in conditions of sodium and fluid overload, such as hypertension and chronic kidney disease pre-dialysis.[2] While these indications are not currently the primary focus, the drug's fundamental mechanism of inhibiting intestinal sodium absorption may warrant future investigation in these areas. As more long-term, real-world data accumulate, the full clinical value and optimal placement of Tenapanor in treatment algorithms will become even clearer. Its future will likely be shaped by the interplay of its demonstrated clinical innovation, its management in real-world practice, and the evolving landscape of market access and healthcare economics.

Works cited

1. Tenapanor: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed September 27, 2025, https://go.drugbank.com/drugs/DB11761
2. Tenapanor - Wikipedia, accessed September 27, 2025, https://en.wikipedia.org/wiki/Tenapanor
3. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2) - PMC, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8183489/
4. Tenapanor in the Treatment of Irritable Bowel Syndrome with Constipation: Discovery, Efficacy, and Role in Management - PMC, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10257918/
5. What is the therapeutic class of Tenapanor Hydrochloride?, accessed September 27, 2025, https://synapse.patsnap.com/article/what-is-the-therapeutic-class-of-tenapanor-hydrochloride
6. What clinical trials have been conducted for Tenapanor Hydrochloride? - Patsnap Synapse, accessed September 27, 2025, https://synapse.patsnap.com/article/what-clinical-trials-have-been-conducted-for-tenapanor-hydrochloride
7. Tenapanor Improves Abdominal Symptoms Irrespective of Changes in Complete Spontaneous Bowel Movement Frequency in Adults with Irritable Bowel Syndrome with Constipation | Digestive Diseases | Karger Publishers, accessed September 27, 2025, https://karger.com/ddi/article/43/2/146/918402/Tenapanor-Improves-Abdominal-Symptoms-Irrespective
8. (PDF) Efficacy of Tenapanor in Treating Patients With Irritable Bowel ..., accessed September 27, 2025, https://www.researchgate.net/publication/338579438_Efficacy_of_Tenapanor_in_Treating_Patients_With_Irritable_Bowel_Syndrome_With_Constipation_A_12-Week_Placebo-Controlled_Phase_3_Trial_T3MPO-1
9. (PDF) Efficacy of Tenapanor in Treating Patients With Irritable Bowel ..., accessed September 27, 2025, https://www.researchgate.net/publication/347863889_Efficacy_of_Tenapanor_in_Treating_Patients_With_Irritable_Bowel_Syndrome_With_Constipation_A_26-Week_Placebo-Controlled_Phase_3_Trial_T3MPO-2
10. Tenapanor (oral route) - Side effects & dosage - Mayo Clinic, accessed September 27, 2025, https://www.mayoclinic.org/drugs-supplements/tenapanor-oral-route/description/drg-20471207
11. FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor | Ardelyx, accessed September 27, 2025, https://ir.ardelyx.com/news-releases/news-release-details/fda-approves-xphozahr-tenapanor-first-class-phosphate-absorption
12. Report on the Deliberation Results August 25, 2023 Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental H, accessed September 27, 2025, https://www.pmda.go.jp/files/000271700.pdf
13. Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM) - PMC, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8785778/
14. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY) - PubMed Central, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8259655/
15. Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients - PMC, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8418975/
16. IBSRELA® (tenapanor) Clinical Safety Data | For US HCPs, accessed September 27, 2025, https://www.ibsrela-hcp.com/safety/
17. XPHOZAH (tenapanor) Tablets | For US Healthcare Professionals, accessed September 27, 2025, https://xphozah-hcp.com/
18. IBSRELA (tenapanor) tablets, for oral use - accessdata.fda.gov, accessed September 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211801s004lbl.pdf
19. Tenapanor | C50H66Cl4N8O10S2 | CID 71587953 - PubChem, accessed September 27, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/71587953
20. Tenapanor hydrochloride | DrugBank Online, accessed September 27, 2025, https://go.drugbank.com/salts/DBSALT002068
21. Tenapanor: First Approval - ResearchGate, accessed September 27, 2025, https://www.researchgate.net/publication/336970039_Tenapanor_First_Approval
22. Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats - PubMed, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/33283643/
23. Tenapanor free base | AZD-1722 | CAS#1234423-95-0 | 1234365-97-9 | Na+/H+ exchanger 3 (NHE3) inhibitor - MedKoo Biosciences, accessed September 27, 2025, https://www.medkoo.com/products/13303
24. Tenapanor | NHE3 inhibitor | Buy from Supplier AdooQ®, accessed September 27, 2025, https://www.adooq.com/tenapanor.html
25. Tenapanor | CAS NO.:1234423-95-0 - GlpBio, accessed September 27, 2025, https://www.glpbio.com/tenapanor.html
26. TENAPANOR - New Drug Approvals, accessed September 27, 2025, https://newdrugapprovals.org/2019/06/28/tenapanor/
27. Tenapanor | RDX5791 | Benzene Compounds - Ambeed.com, accessed September 27, 2025, https://www.ambeed.com/products/tenapanor.html
28. Tenapanor | C50H66Cl4N8O10S2 | CID 71587953 - PubChem, accessed September 27, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Tenapanor
29. Ibsrela, Xphozah (tenapanor) dosing, indications, interactions, adverse effects, and more, accessed September 27, 2025, https://reference.medscape.com/drug/ibsrela-xphozah-tenapanor-1000311
30. This label may not be the latest approved by FDA. For current ..., accessed September 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213931s000lbl.pdf
31. Tenapanor (AZD1722) | NHE3 Inhibitor - MedchemExpress.com, accessed September 27, 2025, https://www.medchemexpress.com/Tenapanor.html
32. CAS 1234423-95-0 Tenapanor - BOC Sciences, accessed September 27, 2025, https://www.bocsci.com/tenapanor-cas-1234423-95-0-item-475197.html
33. Mechanism of action. Tenapanor inhibits NHE3, which transports luminal... - ResearchGate, accessed September 27, 2025, https://www.researchgate.net/figure/Mechanism-of-action-Tenapanor-inhibits-NHE3-which-transports-luminal-sodium-in-exchange_fig1_347863889
34. Drug Treatment for Irritable Bowel Syndrome with Constipation Granted FDA Approval, accessed September 27, 2025, https://www.pharmacytimes.com/view/drug-treatment-for-irritable-bowel-syndrome-with-constipation-granted-fda-approval
35. IBSRELA® (tenapanor) | For US HCPs, accessed September 27, 2025, https://www.ibsrela-hcp.com/
36. XPHOZAH (tenapanor) Tablets | Learn About XPHOZAH, accessed September 27, 2025, https://xphozah.com/
37. Tenapanor: A new treatment option for hyperphosphatemia in end stage kidney disease, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/35041802/
38. Tenapanor-A Novel Approach for Management of Hyperphosphatemia in End Stage Renal Disease: A Clinical Study Aggregate Review - ResearchGate, accessed September 27, 2025, https://www.researchgate.net/publication/377420415_Tenapanor-A_Novel_Approach_for_Management_of_Hyperphosphatemia_in_End_Stage_Renal_Disease_A_Clinical_Study_Aggregate_Review
39. pmc.ncbi.nlm.nih.gov, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10257918/#:~:text=Tenapanor's%20mechanism%20of%20action.,It%20reduces%20visceral%20hypersensitivity.
40. Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023, accessed September 27, 2025, https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-showcased-encouraging-data-treatment-satisfaction-and
41. Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis - PMC, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11062617/
42. Tenapanor for irritable bowel syndrome with constipation - NIHR Innovation Observatory, accessed September 27, 2025, https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/6704-Tenapanor-for-IBS-C-V1.0-NONCONF.pdf
43. Linaclotide vs Tenapanor Comparison - Drugs.com, accessed September 27, 2025, https://www.drugs.com/compare/linaclotide-vs-tenapanor
44. Tenapanor (Ibsrela) for the Treatment of Irritable Bowel Syndrome With Constipation - AAFP, accessed September 27, 2025, https://www.aafp.org/pubs/afp/issues/2022/0600/p656.html
45. IBSRELA® (tenapanor) Clinical Efficacy Data | For US HCPs, accessed September 27, 2025, https://www.ibsrela-hcp.com/efficacy/
46. Ibsrela (tenapanor) FDA Approval History - Drugs.com, accessed September 27, 2025, https://www.drugs.com/history/ibsrela.html
47. tenapanor (Ibsrela®, Xphozah®) - EOCCO, accessed September 27, 2025, https://www.eocco.com/-/media/EOCCO/PDFs/Formulary/tenapanor-Ibsrela.pdf
48. Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo - Harvard DASH, accessed September 27, 2025, https://dash.harvard.edu/bitstreams/7312037e-3a61-6bd4-e053-0100007fdf3b/download
49. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1) - PubMed, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/31934897/
50. Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C, accessed September 27, 2025, https://ir.ardelyx.com/static-files/a18c667d-4a74-4353-86d1-ae1acd9382eb
51. About IBSRELA® (tenapanor) & IBS-C Treatment, accessed September 27, 2025, https://www.ibsrela.com/about/
52. Tenapanor in Hyperphosphatemia Is Effective but Has Cost, Market ..., accessed September 27, 2025, https://www.pharmacytimes.com/view/tenapanor-in-hyperphosphatemia-is-effective-but-has-cost-market-barriers
53. Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats | Request PDF - ResearchGate, accessed September 27, 2025, https://www.researchgate.net/publication/347405980_Combination_treatment_with_tenapanor_and_sevelamer_synergistically_reduces_urinary_phosphorus_excretion_in_rats
54. Xphozah (tenapanor) FDA Approval History - Drugs.com, accessed September 27, 2025, https://www.drugs.com/history/xphozah.html
55. Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Trial - PR Newswire, accessed September 27, 2025, https://www.prnewswire.com/news-releases/ardelyx-announces-publication-of-52-week-phase-3-phreedom-trial-301368919.html
56. Ardelyx's tenapanor reduces mean serum phosphorus in Phase III CKD trial, accessed September 27, 2025, https://www.clinicaltrialsarena.com/news/ardelyx-tenapanor-ckd-trial/
57. (PDF) A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY) - ResearchGate, accessed September 27, 2025, https://www.researchgate.net/publication/350439661_A_Randomized_Trial_of_Tenapanor_and_Phosphate_Binders_as_a_Dual-Mechanism_Treatment_for_Hyperphosphatemia_in_Patients_on_Maintenance_Dialysis_AMPLIFY
58. Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment, accessed September 27, 2025, https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-announces-positive-results-pivotal-phase-3-amplify-study
59. Ardelyx's Tenapanor Hits the Mark in CKD Trial - BioSpace, accessed September 27, 2025, https://www.biospace.com/ardelyx-s-tenapanor-hits-the-mark-in-ckd-trial
60. End Stage Renal Diseases Completed Phase 4 Trials for Tenapanor (DB11761) - DrugBank, accessed September 27, 2025, https://go.drugbank.com/indications/DBCOND0079281/clinical_trials/DB11761?phase=4&status=completed
61. David P. Rosenbaum1, Yang Yang1, Arnold L. Silva2, German T. Hernandez3 - NET, accessed September 27, 2025, https://coursesv4bbs.blob.core.windows.net/nkf/content-item/a45c3ceb-4b35-469c-824b-ea975e3c2def/poster-216_rosenbaum_normalize_poster_final.pdf
62. Tenapanor improves long-term control of high phosphate concentrations in the blood in patients receiving maintenance dialysis: a plain language summary of the NORMALIZE study, accessed September 27, 2025, https://www.tandfonline.com/doi/pdf/10.1080/03007995.2024.2364824
63. 211801Orig1s000 | FDA, accessed September 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211801Orig1s000Lbl.pdf
64. Other Review(s) - accessdata.fda.gov, accessed September 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211801Orig1s000OtherR.pdf
65. Efficacy and Safety of Tenapanor in Hemodialysis Patients with Hyperphosphatemia: A Systematic Review and Meta-Analysis of Short-Term Randomized Controlled Trials - Karger Publishers, accessed September 27, 2025, https://karger.com/ajn/article/doi/10.1159/000546265/930214/Efficacy-and-safety-of-tenapanor-in-hemodialysis
66. IBSRELA® (tenapanor) | IBS-C Treatment For Adult Patients, accessed September 27, 2025, https://www.ibsrela.com/
67. Tenapanor Approved for Adults with IBS-C - Drug Topics, accessed September 27, 2025, https://www.drugtopics.com/view/tenapanor-approved-adults-ibs-c
68. Prescribing IBSRELA® (tenapanor) | For US HCPs, accessed September 27, 2025, https://www.ibsrela-hcp.com/prescribing-ibsrela/
69. Constipation Agents C24671-A - Molina Healthcare, accessed September 27, 2025, https://www.molinahealthcare.com/-/media/Molina/PublicWebsite/PDF/Providers/common/pa-criteria/Constipation-Agents-C24671-A.pdf
70. Tenapanor (XPHOZAH®): First FDA Approved Phosphate Absorption Inhibitor - Pennsylvania Society of Health-System Pharmacists, accessed September 27, 2025, https://www.pshp.org/news/680699/Tenapanor-XPHOZAH-First-FDA-Approved-Phosphate-Absorption-Inhibitor.htm
71. Tenapanor (Xphozah): MedlinePlus Drug Information, accessed September 27, 2025, https://medlineplus.gov/druginfo/meds/a624003.html
72. Tenapanor hydrochloride - KEGG DRUG, accessed September 27, 2025, https://www.kegg.jp/entry/D11653
73. European Medicines Agency (EMA), accessed September 27, 2025, https://www.ema.europa.eu/en/medicines
74. Annexes – 2024 annual report of the European Medicines Agency, accessed September 27, 2025, https://www.ema.europa.eu/en/documents/annual-report/annexes-2024-annual-report-european-medicines-agency_en.pdf
75. Getting Started with IBSRELA, accessed September 27, 2025, https://www.ibsrela.com/starting-ibsrela/
76. Ibsrela vs. Linzess for Constipation and Irritable Bowel Syndrome ..., accessed September 27, 2025, https://www.goodrx.com/compare/ibsrela-vs-linzess
77. Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis - PubMed, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/30144426/
78. Ibsrela vs. Amitiza for Constipation and Irritable Bowel Syndrome ..., accessed September 27, 2025, https://www.goodrx.com/compare/ibsrela-vs-amitiza
79. Ibsrela vs Lubiprostone Comparison - Drugs.com, accessed September 27, 2025, https://www.drugs.com/compare/ibsrela-vs-lubiprostone
80. Amitiza vs Ibsrela Comparison - Drugs.com, accessed September 27, 2025, https://www.drugs.com/compare/amitiza-vs-ibsrela
81. Efficacy of tenapanor in managing hyperphosphatemia and constipation in hemodialysis patients: A randomized controlled trial - PMC, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12173349/
82. Full article: Efficacy and safety of tenapanor in end-stage renal disease patients with hyperphosphatemia: a systematic review and meta-analysis, accessed September 27, 2025, https://www.tandfonline.com/doi/full/10.1080/0886022X.2024.2410389
83. Tenapanor Recruiting Phase 3 Trials for Irritable Bowel Syndrome With Constipation (IBS-C) Treatment - DrugBank, accessed September 27, 2025, https://go.drugbank.com/drugs/DB11761/clinical_trials?conditions=DBCOND0064306&phase=3&purpose=treatment&status=recruiting
84. Constipation Recruiting Phase 3 Trials for Tenapanor (DB11761) | DrugBank Online, accessed September 27, 2025, https://go.drugbank.com/indications/DBCOND0004520/clinical_trials/DB11761?phase=3&status=recruiting